By Christopher P. Singer ---
MedImmune and sanofi pasteur announced today that they have entered into a licensing agreement concerning certain of MedImmune's intellectual property relating to virus generation. Specifically, sanofi pasteur has licensed MedImmune's "reverse genetics" technology which provides the ability to make viruses from DNA segments. Sanofi pasteur intends to use the reverse genetics technology to develop and produce new human seasonal, pre-pandemic, and pandemic influenza vaccines. The technology provides added safety for manufacturers as it allows them to avoid direct contact with infectious viral strains by using only fragments of the particular viral genome.
Under the agreement, sanofi pasteur will make an initial payment to MedImmune, and MedImmune may also receive royalty payments based on sales of vaccine stocks and other products developed using the reverse genetics technology.
Comments